Lannett Reports Updates of Biosimilar Insulin Glargine
Shots:
- The company provided updates on the clinical study evaluating the PK & PD of biosimilar insulin glargine that was jointly developed by Lannett & HEC Group of companies
- 50% of the patients enrolled in the study have received the first of the two doses whereas 33.3% of the patients have received the second dose. There were no AEs indicated from the study so far & the company will present the results from the study by the end of 2022
- Lannett expects to file a BLA for its biosimilar to be evaluated in comparison with Sanofi’s Lantus in early 2023 & also expects to commercialize biosimilar insulin glargine by H1’24
Ref: PR Newswire | Image: Lannett
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
